InoLife Technologies enters into USD48,000 bridge loan financing with Lewis Family Group Fund
M2 - Tue Apr 07, 6:47AM CDT
Healthcare company InoLife Technologies (Other OTC:INOL) reported on Monday that it has completed a USD48,000 bridge loan with Lewis Family Group Fund.
InoLife Technologies Closes Bridge Loan Financing With Lewis Family Group Fund
GlobeNewswire - Mon Apr 06, 9:30AM CDT
InoLife Technologies, Inc. (OTC:INOL), a service-based healthcare product marketing company, announced that on March 31, 2015 it closed a $48,000 bridge loan with Lewis Family Group Fund LP (the "Lewis Fund"
INOL Announces Launch of Kumi Discovery Campaign
Marketwired - Mon Nov 24, 7:02AM CST
InoLife Technologies Inc., (PINKSHEETS: INOL) announced the roll out of a new line of products which will be under the brand name of Kumi. This line of products will be in the multi-billion dollar skin care and anti-aging industry. The products are produced and developed through a strategic alliance with an ISO 9001:2008 & ISO 14001(2004) accredited pharmaceutical company and WHO GMP certified for all its products and is specialized in the manufacturing of Cephalosporins and its intermediates. The Kumi discovery campaign kicks off with the launch of www.kumiproducts.com
INOL to unveil new Kumi brand product Line
M2 - Wed Nov 05, 6:26AM CST
InoLife Technologies (PINKSHEETS:INOL) revealed on Tuesday the planned availability of its new line of products under the Kumi label in the skin care and anti-aging industry.
INOL Announces New Product Line Under the Brand of Kumi
Marketwired - Tue Nov 04, 8:15AM CST
InoLife Technologies, Inc. (PINKSHEETS: INOL) announced the roll out of a new line of products which will be under the brand name of Kumi. This line of products will be in the multi-billion dollar skin care and anti-aging industry. The products are produced and developed through a strategic alliance with an ISO 9001:2008 & ISO 14001(2004) accredited pharmaceutical company and WHO GMP certified for all its products and is specialized in the manufacturing of Cephalosporins and its intermediates. It has a wide range of products and is fast expanding to meet the present and future market demands for the high value drugs. It manufactures the Active Pharmaceutical Ingredient (API) in bulk quantities for both Indian and international regulated and semi-regulated markets. All the drugs manufactured meet USP / BP / JP standards.